Cutaneous Reactions Due to Sulfamethoxypyridazine

Lindsay, Donald G.

doi:10.1001/archderm.1958.01560090011003

Cited by 17 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a small number of patients, including those with G6PD deficiency, are susceptible to sudden and severe haemolysis, which may occur even at low doses. Stevens–Johnson syndrome, 18 renal failure, hepatitis, bronchiolitis obliterans, alveolitis 19,20 and blood dyscrasias, notably marrow depression and agranulocytosis, have also been reported with SMXP, although we did not encounter any of these. SMXP’s long elimination half‐life, while of value from a dosing point of view, is clearly a problem if adverse effects occur.…”

Section: Discussionmentioning

confidence: 55%

See 1 more Smart Citation

An open clinical trial of sulphamethoxypyridazine in the treatment of mucous membrane pemphigoid

Pemberton

Buchanan

Theaker

2000

British Journal of Dermatology

View full text Add to dashboard Cite

Twenty-five patients with mucous membrane pemphigoid (MMP), whose oral lesions were unresponsive to topical steroid treatment, were treated with 1 g daily of sulphamethoxypyridazine (SMXP), a long-acting sulphonamide antibiotic, in an open prospective clinical trial. Lesion severity was assessed objectively in a semiquantitative fashion before treatment and after 14 weeks of treatment. The patient's subjective assessment of the associated pain or discomfort, using a visual analogue scale, was also recorded at these times. Three patients (12%) were withdrawn from the study owing to side-effects or complications, one due to an allergic reaction, the other two because of significant haemolysis. For the remainder there was a significant improvement in the mean objective clinical scores for desquamative gingivitis, other oral lesions, conjunctival inflammation, nasal, vulvovaginal and skin involvement, after 14 weeks treatment with SMXP (all P < 0.001, except skin P < 0. 01). Only conjunctival scarring showed no improvement. In addition, there was a significant improvement (P < 0.001) in the pain scores for the mouth, eyes, nose, vulvovaginal region and skin. The results indicate that with appropriate monitoring SMXP is an effective treatment for MMP and compares favourably with other systemic agents used in the management of this condition.

show abstract

Section: Discussionmentioning

confidence: 55%

“…Allergic responses usually present as mild cutaneous, erythematous maculopapular eruptions, but severe reactions including Stevens–Johnson syndrome are not uncommon. 18 …”

Section: Discussionmentioning

confidence: 99%

An open clinical trial of sulphamethoxypyridazine in the treatment of mucous membrane pemphigoid

Pemberton

Buchanan

Theaker

2000

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…It is hard to escape the conclusion that sulphamethoxypyridazine was responsible for the skin eruption in this patient. Nine previous cases of severe bullous erythema have been reported in association with this drug (Lindsay et al, 1958;Salvaggio and Gonzalez, 1959;Garner, 1959;Yaffee, 1959: Maher-Loughnan andTullis. 1960).…”

Section: Medical Memorandamentioning

confidence: 99%

“…Minor effects that have been reported are headache, nausea, anorexia, fever, giddiness, joint pains, and mild skin eruptions. Their incidence is difficult to assess: estimates vary from 3.6% (Stewart et al, 1960) to 15% MEDICAL MEMORANDA MEDIBCJR URNAL (Lindsay et al, 1958). In most cases the reactions consist of minor skin eruptions which subside when treatment is stopped.…”

Section: Medical Memorandamentioning

confidence: 99%